Bioton SA
WSE:BIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bioton SA
WSE:BIO
|
PL |
|
D
|
DaVita Inc
F:TRL
|
US |
|
M
|
Mitsui Fudosan Co Ltd
XMUN:MFU
|
JP |
Intrinsic Value
The intrinsic value of Bioton SA (BIO) under the Base Case is 3.68 PLN per share. Compared with the current market price of 3.76 PLN, the stock appears Overvalued by 2% .
The intrinsic value is calculated using the DCF method. The model assumes operating margin rises from 5% last year to 8% by 2033, above its five-year average of 6.4%. If operating margin stayed at its five-year average of 6.4%, the estimate would be about zł2.99.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bioton Does
Bioton SA is a Polish pharmaceutical company best known for making insulin and other medicines linked to diabetes care. It also produces active pharmaceutical ingredients, which are the chemical substances that drug makers use to manufacture finished medicines. In simple terms, Bioton sits in the middle of the drug supply chain: it makes both the key ingredients and some finished pharmaceutical products.
- Headquarters
- Poland PL
- Employees
- 371
- IPO date
- Mar 16, 2005
Revenue & Expenses Breakdown
Bioton SA
Earnings Waterfall
Bioton SA
The intrinsic value for Bioton SA (BIO) under the Base Case is 3.68 PLN.
Compared with the current market price of 3.76 PLN, the stock appears Overvalued by 2% .